We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+18.11%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
19.96%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.25M |
| 2 |
Gilead Sciences
GILD
|
+$6.13M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$6.05M |
| 4 |
Amgen
AMGN
|
+$5.9M |
| 5 |
Adobe
ADBE
|
+$5.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.85M |
| 2 |
Analog Devices
ADI
|
+$3.37M |
| 3 |
Amazon
AMZN
|
+$3.21M |
| 4 |
lululemon athletica
LULU
|
+$2.87M |
| 5 |
Oracle
ORCL
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
201
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $208K | 0.04% |
5,471
+4,354
| +390% | +$93.3K |
|
202
Ironwood Pharmaceuticals
IRWD
$714M
| $207K | 0.04% |
18,061
+14,064
| +352% | +$139K |
|
203
Lam Research
LRCX
$408B
| $204K | 0.04% |
2,600
-2,340
| -47% | -$159K |
|
204
Danaher
DHR
$145B
| $202K | 0.04% |
871
-111
| -11% | -$23.6K |
|
205
Mondelez International
MDLZ
$79.4B
| $197K | 0.04% |
2,707
-2,362
| -47% | -$162K |
|
206
Vericel Corp
VCEL
$2.29B
| $197K | 0.04% |
+5,521
| New | +$192K |
|
207
Myriad Genetics
MYGN
$309M
| $196K | 0.04% |
10,253
+8,152
| +388% | +$141K |
|
208
Zoetis
ZTS
$30.4B
| $195K | 0.04% |
986
| – | – |
|
209
Automatic Data Processing
ADP
$107B
| $192K | 0.04% |
821
-714
| -47% | -$166K |
|
210
AbCellera Biologics
ABCL
$3.18B
| $192K | 0.04% |
33,566
+26,143
| +352% | +$121K |
|
211
NovoCure
NVCR
$2.05B
| $185K | 0.04% |
12,363
+9,624
| +351% | +$129K |
|
|
MRUS
212
DELISTED
Merus
MRUS
| $184K | 0.04% |
6,681
+5,204
| +352% | +$122K |
|
213
Supernus Pharmaceuticals
SUPN
$2.78B
| $183K | 0.04% |
6,314
+4,913
| +351% | +$130K |
|
214
Pacira BioSciences
PCRX
$945M
| $181K | 0.04% |
5,373
+4,188
| +353% | +$123K |
|
|
HSAI
215
Hesai Group
HSAI
$2.99B
| $178K | 0.03% |
+20,000
| New | +$195K |
|
216
Structure Therapeutics
GPCR
$3.83B
| $177K | 0.03% |
4,349
+2,939
| +208% | +$168K |
|
217
Zoom
ZM
$30.8B
| $175K | 0.03% |
2,440
-948
| -28% | -$62.7K |
|
218
Syndax Pharmaceuticals
SNDX
$1.77B
| $174K | 0.03% |
8,058
+6,276
| +352% | +$96.5K |
|
219
Constellation Brands
STZ
$22.9B
| $172K | 0.03% |
+713
| New | +$170K |
|
220
Ardelyx
ARDX
$1.03B
| $166K | 0.03% |
26,851
+21,259
| +380% | +$95.4K |
|
|
MORF
221
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $166K | 0.03% |
5,753
+4,515
| +365% | +$108K |
|
222
Kymera Therapeutics
KYMR
$9.48B
| $164K | 0.03% |
6,423
+5,002
| +352% | +$89.5K |
|
|
GRFS
223
Grifois
GRFS
$5.4B
| $163K | 0.03% |
14,111
+10,979
| +351% | +$102K |
|
224
Disc Medicine
IRON
$3.09B
| $161K | 0.03% |
+2,793
| New | +$143K |
|
|
225
lululemon athletica
LULU
$13.7B
| $161K | 0.03% |
315
-6,649
| -95% | -$2.87M |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q4 2023 Portfolio in Review
As of Q4 2023, China Universal Asset Management Company held 503 positions worth $514M, up 49% from $345M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
China Universal Asset Management Company deployed $103M of net new capital in Q4 2023, opening 57 new positions and adding to 239 existing holdings. Its largest new stake was GSK: 54,345 shares worth $2.03M.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $4.85M trimmed.
- China Universal Asset Management Company's largest Q4 2023 buy was GSK: 54,345 shares worth $2.03M.
- China Universal Asset Management Company added most to Vertex Pharmaceuticals in Q4 2023, an estimated $6.25M increase.
- China Universal Asset Management Company's biggest Q4 2023 reduction was NVIDIA, cutting an estimated $4.85M.
- China Universal Asset Management Company fully exited Oracle in Q4 2023, selling an estimated $1.91M.
- China Universal Asset Management Company's ten largest holdings make up 27% of its $514M portfolio in Q4 2023.
- China Universal Asset Management Company opened 57 new positions and closed 78 in Q4 2023.
- China Universal Asset Management Company's portfolio value rose 49% quarter-over-quarter to $514M.
Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.